MarcoLuisDavilaMDPhD

PubMed

• 977 citations
  Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias
  Renier J. Brentjens, Isabelle Riviere, Jae H. Park, Marco L. Davila, Xiuyan Wang
  Blood. 2011-11-03
• 60 citations
  NKG2D-based chimeric antigen receptor therapy induced remission in a relapsed/refractory acute myeloid leukemia patient
  David A. Sallman, Jason Brayer, Elizabeth M. Sagatys, Caroline Lonez, Eytan Breman
  Haematologica. 2018-09-01
• 143 citations
  Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events
  Marcela V. Maus, Sara Alexander, Michael R. Bishop, Jennifer N. Brudno, Colleen Callahan
  Journal for Immunotherapy of Cancer. 2020-12-01

Journal Articles

• CARs move to the Fast Lane  
  Davila ML and Papetrou E, Molecular Therapy, 1/1/2014
• Chimeric Antigen Receptors for the Adoptive T Cell Therapy Of Hematologic Malignancies  
  Davila, ML, Bouhassira DC, Park JH, Curran KJ, Smith EL, Pegram HJ, and Brentjens R., International Journal of Hematology, 1/1/2014
• Chimeric Antigen Receptor Therapy for Chronic Lymphocytic Leukemia: What are the Challenges?  
  Davila ML, Brentjens R, Hematol Oncol Clin North Am, 1/1/2013
• CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with ChemotherapyRefractory Acute Lymphoblastic Leukemia  
  Brentjens RJ, Davila ML, Riviere I, Park J, Wang X, et al., Sci Transl Med, 1/1/2013
• Early Clinical Outcomes of Chimeric Antigen Receptor Modified T Cells and the Generation of "Armored" CAR T Cells for Future Applications to Cancer Immunotherapy  
  Davila, ML, Brentjens, R, Am Assoc Cancer Res Educ Book, 1/1/2013
• How Do CARs Work?: Early Insights from Recent Clinical Studies Targeting CD19  
  Davila ML, Brentjens R, Wang X, Riviere I, Sadelain M, Oncoimmunology, 1/1/2012
• Conserved Cryptic Recombination Signals in Vkappa Gene Segments Are Cleaved in Small Pre-B Cells  
  Lieberman AE, Kuraoka M, Davila M, Kelsoe G, Cowell LG, BMC Immunol, 1/1/2009
• Multiple, Conserved Cryptic Recombination Signals in VH Gene Segments: Detection of Cleavage Products Only in Pro B Cells  
  Davila M, Liu F, Cowell LG, Lieberman AE, Heikamp E, et al., J Exp Med, 1/1/2007
• Computational Tools for Understanding Sequence Variability in Recombination Signals  
  Cowell LG, Davila M, Ramsden D, Kelsoe G, Immunol Rev, 1/1/2004
• Prospective Estimation of Recombination Signal Efficiency and Identification of Functional Cryptic Signals in the Genome by Statistical Modeling  
  Cowell LG, Davila M, Yang K, Kepler TB, Kelsoe G, J Exp Med, 1/1/2003
• Identification and Utilization of Arbitrary Correlations in Models of Recombination Signal Sequences  
  Cowell LG, Davila M, Kepler TB, Kelsoe G, Genome Biol, 1/1/2002
• A Role for Secondary V(D)J Recombination in Oncogenic Chromosomal Translocations?  
  Davila M, Foster S, Kelsoe G, Yang K, Adv Cancer Res, 1/1/2001
• Do Germinal Centers Have a Role in the Generation of Lymphomas?  
  Yang K, Davila M, Kelsoe G, Curr Top Microbiol Immunol, 1/1/1999
• Join now to see all

Abstracts/Posters

• Human CD83 Targeted Chimeric Antigen Receptor T Cell for the Prevention of Graft Versus Host Disease and Treatment of Myeloid Leukemia
  Marco L. Davila, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• The Lymphoma Tumor Microenvironment Influences Toxicity after CD19 CAR T Cell Therapy
  Marco L. Davila, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Mutation of the CD28 Co-Stimulatory Domain Confers Enhanced CAR T Cell Function
  Marco L. Davila, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• MDSC Suppression of CAR T Cells Can be Reduced By Targeted Signaling Disruption
  Marco L. Davila, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Fever Characteristics Associated with Toxicity and Outcome after Anti-CD19 CAR T-Cell Therapy for Aggressive Lymphoma
  Marco L. Davila, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Tumor Inflammation and Myeloid Derived Suppressor Cells Reduce the Efficacy of CD19 CAR T Cell Therapy in Lymphoma
  Marco L. Davila, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Safe and Effective Re-Induction Of Complete Remissions In Adults With Relapsed B-ALL Using 19-28z CAR CD19-Targeted T Cell Therapy
  M. L. Davila, I. Riviere, X. Wang, S. Bartido, J. Stefanski, Q. He, O. Borquez-Ojeda, C. Taylor, T. Wasielewska, J. Qu, D. C. Bouhassira, Y. J. Bernal, S. Yoo, T. Purd..., ACTO Meeting, ASH Meeting, New Orleans, LA 2013; Osaka, Japan, 2014, 1/1/2014
• CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy Refractory Acute Leukemia
  Renier Brentjens, Marco L. Davila, Isabelle Riviere, Jae Park, Xiuyan Wang, Shirley Bartido, Jolanta Stefankski, Oriana Borquez-Ojeda, Yvette Bernal, Michel Sadelain, ASGCT Meeting, Salt Lake City, UT, 1/1/2013
• Molecular Remission and B Cell Aplasia Induced in a First Cohort of Adults with Relapsed B-ALL Treated with 19-28z CAR-Targeted T Cells
  Marco L Davila, Isabelle Riviere, Xiuyan Wang, Jae H. Park, et al., American Society of Hematology 2012 Meeting, Atlanta, GA, 1/1/2012
• Impact of the Conditioning Chemotherapy On Outcomes in Adoptive T Cell Therapy: Results From a Phase I Clinical Trial of Autologous CD19-Targeted T Cells for Patients ...
  Jae H. Park, Isabelle Rivière, Xiuyan Wang, Jolanta Stefanski, Qing He, Clare Taylor, Malgorzata Olszewska, Teresa Wasielewska, Shirley Bartido, Marco L Davila, et al., American Society of Hematology 2012 Meeting, Atlanta, GA, 1/1/2012
• A Phase I Clinical Trial of Autologous, Anti-CD19 Gene Targeted T Cells for Adults with B Cell Acute Lymphoblastic Leukemia (B-ALL).
  Marco L. Davila, Isabelle Riviere, Xiuyan Wang, et al., American Society of Clinical Oncology 2012 Annual Meeting, Chicago, IL, 1/1/2012
• Conditioning Intensity and T Cell Dose Determine Efficacy of CD19-Targeted T CellMediated Tumor Eradication in an Immunocompetent Mouse Model of B-ALL
  Marco L Davila, Christopher Kloss, Renier J Brentjens, and Michel Sadelain, American Society of Hematology 2012 Meeting, Atlanta, GA, 1/1/2012
• CD19-Targeted Donor T Cells Exert Potent Graft Versus Lymphoma Activity and Attenuated GVHD.
  Arnab Ghosh, Marco L Davila, Lauren F. Young, Christopher Kloss, et al., American Society of Hematology Meeting, Atlanta, GA, 1/1/2012
• B Cell Aplasia In a Patient with Relapsed B Cell Acute Lymphoblastic Leukemia Following Re-Induction and Consolidation with Autologous T Cells Genetically Targeted to ...
  Marco L Davila, Clare Taylor, Xiuyan Wang, Jolanta Stefanski, Malgorzata Olszewska, Shirley Bartido, Mark Frattini, Michel Sadelain, Isabelle Rivière, and Renier J. Br..., American Society of Hematology 2010 Meeting, Orlando, FL, 1/1/2010
• T Cells Genetically Targeted to CD19 Eradicate B-ALL In a Novel Syngeneic Mouse Disease Model.
  Marco L Davila and Michel Sadelain, American Society of Hematology Meeting, Orlando, FL, 1/1/2010
• VH Gene Replacement Occurs during the Pro-B Stage of Development
  Davila M, E Heikamp, LG Cowell, and G Kelsoe., American Association of Immunologists Meeting, Denver, Colorado, 1/1/2003
• Does the V(D)J Recombinase Mediate Chromosomal Translocations?
  Marco Davila, Kaiyong Yang, and Garnett Kelsoe, American Association of Immunologists Meeting, Orlando, Florida, 1/1/2001
• Rag1 and Rag2 in the Periphery
  Marco Davila, Sandra Foster, and Garnett Kelsoe., Canadian Society of Immunologist Meeting, Alberta, Canada, 1/1/2001
• An Association between V(D)J Rearrangement and Chromosomal Translocations.
  Marco Davila, Kaiyong Yang, and Garnett Kelsoe, 15th Annual M.D./Ph.D. Conference, Aspen, Colorado, 1/1/2000
• An In Vitro model for Chromosomal Translocations Driven by RAG1/2.
  Marco Davila, Kaiyong Yang, and Garnett Kelsoe, International Conference on Lymphoma, Lugano, Switzerland, 1/1/1999
• The Germinal Center and Lymphomagenesis.
  Marco Davila, Kaiyong Yang, and Garnett Kelsoe., Conferencia Internacional de Lymphoma, Mexico City, Mexico, 1/1/1999
• Join now to see all

Lectures

• Prediction of CAR T-Related Toxicities in R/R DLBCL Patients Treated with Axicabtagene Ciloleucel Using Point of Care Cytokine Measurements 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Phase 1 Studies Assessing the Safety and Clinical Activity of Multiple Doses of a NKG2D-Based CAR-T Therapy, Cyad-01, in Acute Myeloid Leukemia 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Aged CAR T Cells Exhibit Enhanced Cytotoxicity and Effector Function but Shorter Persistence and Less Memory-like Phenotypes 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018